In the phase III ALESIA, enrolling only Asian patients with ALK-rearranged advanced NSCLC, alectinib at 600 mg twice daily (n = 125) was compared with crizotinib at 250 mg twice daily (n = 62) as first-line treatment. Here, ALK is linked to non-small cell lung carcinoma.